http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Aug 2026 11:58:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html <div class="xn-content"> <p><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received the final approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Lupin+Announces+Approval+from+U.S.+FDA+for+Pitolisant+Tablets/26936786.html Mon, 17 Aug 2026 11:58:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN O.01520983 O.03319887 O.20026344 REUTERS http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html Mon, 10 Aug 2026 11:48:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.20026344 http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html Mon, 10 Aug 2026 11:48:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.20026344 http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html Mon, 10 Aug 2026 11:48:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.20026344 http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html Mon, 10 Aug 2026 11:48:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.20026344 http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html Mon, 10 Aug 2026 11:48:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.20026344 http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html Mon, 10 Aug 2026 11:48:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.20026344 http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. <span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Lupin+Announces+the+Approval+of+Sodium+Zirconium+Cyclosilicate+for+Oral+Suspension+in+the+United+States/26896287.html Mon, 10 Aug 2026 11:48:00 -0400 500257 500257 A.01721546 A.06822034 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.20026344